Patients with WHO grade II glioma may respond to chemotherapy that is currently not standardized regarding timing and treatment duration. Metabolic changes during chemotherapy may precede structural tumor volume reductions. We therefore compared time courses of amino acid PET and MRI responses to temozolomide (TMZ) and assessed whether responses correlated with seizure control and progression-free survival (PFS).
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas
Rudà, Roberta;SOFFIETTI, Riccardo
Last
2016-01-01
Abstract
Patients with WHO grade II glioma may respond to chemotherapy that is currently not standardized regarding timing and treatment duration. Metabolic changes during chemotherapy may precede structural tumor volume reductions. We therefore compared time courses of amino acid PET and MRI responses to temozolomide (TMZ) and assessed whether responses correlated with seizure control and progression-free survival (PFS).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Neuro Oncol-2016-Roelcke-744-51.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
206.87 kB
Formato
Adobe PDF
|
206.87 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Neuro Oncol-2016.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
532.56 kB
Formato
Adobe PDF
|
532.56 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
